BIOSYNEX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.1 EUR | -2.30% |
|
+10.87% | -38.92% |
| 2023 | Biosynex: merger with Theradiag completed | CF |
| 2023 | Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 383M 408M | Sales 2022 | 197M 210M | Capitalization | 141M 151M |
|---|---|---|---|---|---|
| Net income 2021 | 104M 111M | Net income 2022 | 15M 16.02M | EV / Sales 2021 | 0.5 x |
| Net cash position 2021 | 96.72M 103M | Net cash position 2022 | 35.09M 37.47M | EV / Sales 2022 | 0.54 x |
| P/E ratio 2021 |
2.63
x | P/E ratio 2022 |
9.08
x | Employees | 551 |
| Yield 2021 |
7.6% | Yield 2022 |
-
| Free-Float | 39.43% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.53% | ||
| 1 week | +11.74% | ||
| Current month | +6.75% | ||
| 1 month | +9.36% | ||
| 3 months | -40.37% | ||
| 6 months | -40.02% | ||
| Current year | -38.44% |
1 week
4.56
5.64
1 month
4.565.64
Current year
4.538.97
1 year
4.5311.00
3 years
4.5328.78
5 years
2.5230.38
10 years
2.0930.38
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Lamy
FOU | Founder | - | 05-03-14 |
Larry Abensur
CEO | Chief Executive Officer | 69 | 05-03-14 |
Thierry Paper
FOU | Founder | 60 | 05-03-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thierry Paper
FOU | Founder | 60 | 05-03-14 |
Thomas Lamy
FOU | Founder | - | 05-03-14 |
Larry Abensur
CEO | Chief Executive Officer | 69 | 05-03-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 5.1 | -2.30% | 11 754 |
| 24-04-17 | 5.22 | +13.48% | 57,237 |
| 24-04-16 | 4.6 | 0.00% | 2,802 |
| 24-04-15 | 4.6 | 0.00% | 4,090 |
| 24-04-12 | 4.6 | 0.00% | 6,892 |
Real-time Euronext Paris, April 18, 2024 at 04:25 am EDT
More quotes
Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas:
- manufacturing of diagnosis tests for own account;
- sale of diagnosis tests supplied by other manufacturers of semi-finished products;
- research and development services for third party;
- sale of licenses;
- sale of biological reagents.
At the end of 2022, the group had one production site located in France.
France accounts for 61.1% of net sales.
| 1st Jan change | Capi. | |
|---|---|---|
| -38.44% | 59.76M | |
| -0.40% | 12.58B | |
| -19.65% | 6.82B | |
| -3.32% | 5.14B | |
| -7.82% | 4.22B | |
| -0.84% | 4.21B | |
| -47.89% | 3.47B | |
| +8.57% | 2.65B | |
| -8.06% | 2.25B | |
| -2.61% | 1.69B |
- Stock Market
- Equities
- ALBIO Stock
